Loading
Renal Cell Carcinoma Treatment · Journal article
Journal of Immunotherapy · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective series of 12 patients with residual metastases after ICI response who underwent surgical resection (11) or radiosurgery (1) reports zero recurrences over mean 5.9 years of follow-up. The study is uncontrolled and small, generating a hypothesis that local therapy may improve outcomes in selected ICI responders with isolated residual disease, but lacks the design and power to establish efficacy or change practice.
Retrospective cohort study. Patients with melanoma or renal cell carcinoma with operable residual metastasis after major radiographic response to immune checkpoint inhibitor therapy.. Intervention: Local therapy: surgical removal (n=11) or radiosurgery (n=1) of residual metastatic lesion. n = 12.
12 patients (8 melanoma, 4 RCC) with operable residual metastasis after major ICI response 83.3% (10 of 12) of resected lesions contained viable tumor; 16.7% (2 of 12) showed no viable tumor on pathology All 12 patients had no evidence of recurrence for entire follow-up duration
No report of progression-free or overall survival, adverse events, or quality of life data
While zero recurrence in a small series over extended follow-up is noteworthy, the retrospective uncontrolled design prevents determination of whether this outcome reflects local therapy efficacy, patient selection, or natural disease biology in ICI responders. Clinicians should view this as a signal warranting prospective study, not as evidence to routinely recommend local therapy in this setting.
Retrospective case series of 12 patients with no concurrent control group, reporting observational outcomes of local therapy after ICI; suggestive but uncontrolled, and too small to guide practice change.
As stated by the source record.
Quoted from the source exactly as published.
While zero recurrence in a small series over extended follow-up is noteworthy, the retrospective uncontrolled design prevents determination of whether this outcome reflects local therapy efficacy, patient selection, or natural disease biology in ICI responders. Clinicians should view this as a signal warranting prospective study, not as evidence to routinely recommend local therapy in this setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of melanoma and renal cell carcinoma (RCC). Immune therapy response outcomes are based on radiographic measurements of cancer sites alone, without considering whether these sites contain a viable tumor that has metastatic potential. We hypothesized that ICI may lead to residual radiographic abnormalities that either contain nonviable tumor or tumor without metastatic potential that could be controlled with local therapy. In this retrospective cohort study, we identified 8 patients with melanoma and 4 with RCC who had an operable residual metastasis after major tumor response to ICI treatment. On the basis of histologic analysis, 10 (83.3%) of the resected samples showed viable tumor while 2 (16.7%) showed no viable tumor cells on pathology. After surgical removal (11), or radiosurgery (1), to the lesion, all patients had no evidence of melanoma or RCC recurrence for the duration of follow-up. Time from definitive treatment to last follow-up was a mean of 5.9 years (1.1-11.9 y). ICI therapy in melanoma and RCC may lead to a response where existing lesions or new lesions either have no viable cancer or lose their metastatic capacity. Surgical removal or local radiation to those lesions with residual cancer can render patients' long-term disease-free without the need for additional systemic therapy. Consideration of local therapy approaches in patients with isolated residual metastatic disease after ICI response is clinically justified.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.